Tag Archives: TONADO® 1&2 studies (NCT01431274/NCT01431287)

Boehringer Ingelheim announced new data analyses from the pivotal Phase III TONADO® 1&2 studies (NCT01431274/NCT01431287)

Posted on 21, May 2015 by

In patients with no prior maintenance treatment, tiotropium/olodaterol Respimat® more than doubled the improvement in lung function* compared to Spiriva® Respimat® alone1 Tiotropium/olodaterol Respimat® showed efficacy across all COPD stages with greatest lung function improvements over Spiriva® Respimat® in early … Read the full press release →

Posted in Germany, Healthcare, Pharma & Biotech

Tagged , ,